Physician profile
Gordon W Fried
NPI 1134126840
$95,423.43
in general payments reported to CMS, 2019-2025
38 companies · $2,655 in 2025
The $2,655 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $5,109 · 2021: $14K · 2022: $16K · 2023: $8,121 · 2024: $6,252 · 2025: $2,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,900 · Food and Beverage: $7,832 · Travel and Lodging: $1,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,900.00 |
| Food and Beverage | $7,832.48 |
| Travel and Lodging | $1,295.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $77,542.34 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,976.26 | 2019-2025 | Brilinta, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,870.18 | 2019-2025 | Jardiance |
| Amgen INC. | $1,854.84 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $1,500.27 | 2019-2025 | Avvigo Guidance System |
| Novartis Pharmaceuticals Corporation | $1,389.93 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,157.07 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $1,148.23 | 2019-2025 | |
| Esperion Therapeutics, INC. | $1,060.16 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $793.82 | 2021-2025 | Verquvo, Capvaxive |
| Amarin Pharma, INC. | $663.95 | 2019-2023 | |
| Novo Nordisk INC | $601.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $530.67 | 2021-2025 | |
| Abiomed | $466.53 | 2019-2025 | Impella |
| Scpharmaceuticals INC. | $372.37 | 2023-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $309.29 | 2019-2023 | |
| Atricure, INC. | $255.45 | 2023-2025 | Atriclip Laa Exclusion System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $244.88 | 2019-2024 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $227.22 | 2019-2022 | |
| Vifor Pharma, INC. | $216.06 | 2019-2021 | |
| Abbott Laboratories | $192.53 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Assurity |
| Allergan, INC. | $128.81 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $115.43 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $114.60 | 2020-2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $107.12 | 2020-2024 | Uptravi, Opsumit |
| Lilly USA, LLC | $96.61 | 2025 | Zepbound |
| Regeneron Healthcare Solutions, INC. | $92.69 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $83.24 | 2022-2023 | Arcalyst |
| Genentech USA, INC. | $74.10 | 2020 | |
| Baxter Healthcare | $49.55 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Akcea Therapeutics, INC. | $49.07 | 2020 | |
| Phathom Pharmaceuticals, INC. | $32.20 | 2024 | Voquezna |
| Vivaquant INC, Dba Rhythm Express | $24.80 | 2025 | Rhythm Express |
| Inspire Medical Systems, INC. | $24.54 | 2024 | Inspire |
| Medtronic, INC. | $21.77 | 2023 | Intellis Adaptivestim |
| Sobi, INC | $18.70 | 2021 | |
| Genzyme Corporation | $16.47 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Fried listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.